Sigma Pharmaceuticals (SIP)

The share price of wholesale distributor
Sigma Pharmaceuticals
has rocketed past its peers this year, climbing 90 per cent to be the best performing small cap on the market. But brokers are concerned further upside may be limited, and most recommend a hold. The company will release its first-half result in the coming week and JPMorgan notes it will be the first glimpse into the new structure, after the sale of its pharmaceutical business to Aspen, without being “convoluted" by write-offs, divestitures and other one-offs. Sigma has not provided any specific guidance but did say at the June AGM that trading was “strong."